Corbus Pharmaceuticals Holdings (CRBP) Return on Capital Employed (2014 - 2025)

Corbus Pharmaceuticals Holdings' Return on Capital Employed history runs 12 years deep, the most recent figure standing at 19.6% for Q3 2025.

• On a quarterly basis, Return on Capital Employed rose 469.0% year-over-year to 19.6% in Q3 2025; TTM through Sep 2025 was 19.6%, a 469.0% increase from a year earlier, with the FY2024 full-year figure at 7.86%, up 30062.0% from the prior year.
• Return on Capital Employed slipped to 19.6% in Q3 2025 per CRBP's latest filing, from 9.0% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 9.0% in Q2 2025 and bottomed at 11748.17% in Q4 2023.
• The 5-year median for Return on Capital Employed is 61.07% (2022), against an average of 698.28%.
• Across the five-year window, Return on Capital Employed tumbled 1167881 bps in 2023 and surged 1173219 bps in 2024, its largest moves.
• Year by year, Return on Capital Employed stood at 57.93% in 2021, then retreated by 20 bps to 69.36% in 2022, then plunged by 16838 bps to 11748.17% in 2023, then soared by 100 bps to 15.98% in 2024, then slipped by 23 bps to 19.6% in 2025.
• Per Business Quant, the three latest CRBP Return on Capital Employed figures stand at 19.6% (Q3 2025), 9.0% (Q2 2025), and 16.9% (Q1 2025).